Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 335-345

  Boormans, Joost L ^a   Korsten, Hanneke ^b   Ziel Van Der Made, Angelique J C ^b   Van Leenders, Geert J L H ^b   De Vos, Carola V ^b   Jenster, Guido ^a   Trapman, Jan ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

ERG; gene fusion; prostate cancer; prostate specific; target gene

Indexed keywords

MEMBRANE PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ERG; TUDOR DOMAIN CONTAINING 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ERG GENE; ETV1 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TDRD1 GENE;

AGED; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANS-ACTIVATORS;

EID: 84877825219     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28025     Document Type: Article

References (50)

1. Oikawa T, Yamada T,. Molecular biology of the Ets family of transcription factors. Gene 2003; 303: 11-34.
2. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-51.
3. Mitelman F, Johansson B, Mertens F,. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-45.
4. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
5. Clark JP, Cooper CS,. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-39.
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
7. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-88.
8. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-10.
9. Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457: E1; discussion E2-3.
10. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-24.
11. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-6.
12. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9.
13. Shin S, Kim TD, Jin F, et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 2009; 69: 8102-10.
14. van Weerden WM, de Ridder CM, Verdaasdonk CL, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996; 149: 1055-62.
15. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006; 66: 10658-63.
16. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
17. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8.
18. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 1-12.
19. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75.
20. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-5.
21. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-8.
22. Fitzgerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: Results from a population-based study of prostate cancer. BMC Cancer 2008; 8: 230.
23. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-6.
24. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-403.
25. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not prededictive for PSA recureence, local recurrence, or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012; 25: 471-9.
26. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-63.
27. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-9.
28. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-5.
29. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-52.
30. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-400.
31. Boormans JL, Porkka K, Visakorpi T, et al. Confirmation of the association of TMPRSS2(exon 0)-ERG expression and a favourable prognosis of primary prostate cancer. Eur Urol 2011; 60: 183-4.
32. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
33. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-53.
34. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66: 10242-6.
35. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-25.
36. Barwick BG, Abramovitz M, Kodani M, et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010; 102: 570-6.
37. Jhavar S, Brewer D, Edwards S, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009; 103: 1256-69.
38. Jhavar S, Reid A, Clark J, et al. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn 2008; 10: 50-7.
39. Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-ß signaling. BMC Cancer 2011; 11: 507.
40. Paulo P, Ribeiro FR, Santos J, et al. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 2012; 14: 600-11.
41. Mohamed AA, Tan SH, Sun C, et al. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 2011; 11: 410-7.
42. Vestergaard EM, Nexo E, Torring N, et al. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer 2010; 127: 1857-65.
43. Rickman DS, Chen YB, Banerjee S, et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010; 12: 1031-40.
44. Chen C, Jin J, James DA, et al. Mouse Piwi interactome identifies binding mechanism of Tdrkh Tudor domain to arginine methylated Miwi. Proc Natl Acad Sci USA 2009; 106: 20336-41.
45. Kojima K, Kuramochi-Miyagawa S, Chuma S, et al. Associations between PIWI proteins and TDRD1/MTR-1 are critical for integrated subcellular localization in murine male germ cells. Genes Cells 2009; 14: 1155-65.
46. Chuma S, Hosokawa M, Kitamura K, et al. Tdrd1/Mtr-1, a tudor-related gene, is essential for male germ-cell differentiation and nuage/germinal granule formation in mice. Proc Natl Acad Sci USA 2006; 103: 15894-9.
47. Reuter M, Chuma S, Tanaka T, et al. Loss of the Mili-interacting Tudor domain-containing protein-1 activates transposons and alters the Mili-associated small RNA profile. Nat Struct Mol Biol 2009; 16: 639-46.
48. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 2008; 68: 7541-9.
49. Wei GH, Badis G, Berger MF, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010; 29: 2147-60.
50. Cai C, Hsieh CL, Omwancha J, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007; 21: 1835-46.